Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.

Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK.

Open source

DOI: 10.1016/j.lungcan.2025.108788
Published: 2025-10-03
Container: Lung Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108788,
  title = {Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.},
  author = {Paz-Ares L and  Veillon R and  Majem M and  Zhou C and  Tang KJ and  Kim SW and  Richardson G and  Girard N and  Sanborn RE and  Mansfield AS and  Park K and  Schuchard J and  Diels J and  Sermon J and  Bhattacharya A and  Lorenzini P and  Wortman-Vayn H and  Knoblauch RE and  Agrawal T and  Baig M and  Ono A and  Sabari JK.},
  year = {2026},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2025.108788},
  url = {https://doi.org/10.1016/j.lungcan.2025.108788}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
AU  - Paz-Ares L
AU  -  Veillon R
AU  -  Majem M
AU  -  Zhou C
AU  -  Tang KJ
AU  -  Kim SW
AU  -  Richardson G
AU  -  Girard N
AU  -  Sanborn RE
AU  -  Mansfield AS
AU  -  Park K
AU  -  Schuchard J
AU  -  Diels J
AU  -  Sermon J
AU  -  Bhattacharya A
AU  -  Lorenzini P
AU  -  Wortman-Vayn H
AU  -  Knoblauch RE
AU  -  Agrawal T
AU  -  Baig M
AU  -  Ono A
AU  -  Sabari JK.
PY  - 2026
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2025.108788
UR  - https://doi.org/10.1016/j.lungcan.2025.108788
ER  -

APA

L, P., R, V., M, M., C, Z., KJ, T., SW, K., G, R., N, G., RE, S., AS, M., K, P., J, S., J, D., J, S., A, B., P, L., H, W., RE, K., T, A., M, B., A, O., & JK., S. (2026). Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.. Lung Cancer. https://doi.org/10.1016/j.lungcan.2025.108788

Source records

europe-pmc · retrieved 2026-09-26T14:10:11.369Z